

PHARMACEUTICAL 2022

ABVC BIOPHARMA INC. Rank 336 of 466









PHARMACEUTICAL 2022

ABVC BIOPHARMA INC. Rank 336 of 466



The relative strengths and weaknesses of ABVC BIOPHARMA INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ABVC BIOPHARMA INC. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 36% points. The greatest weakness of ABVC BIOPHARMA INC. is the variable Net Income, reducing the Economic Capital Ratio by 58% points.

The company's Economic Capital Ratio, given in the ranking table, is 30%, being 48% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	9,625
Cost of Goods Sold	5.1
Intangible Assets	0
Liabilities, Current	3,692
Liabilities, Non-Current	1,125
Other Assets	3,547
Other Compr. Net Income	-828
Other Expenses	6,132
Other Liabilities	11
Other Net Income	495
Other Revenues	356
Property and Equipment	526
Research and Development	1,004
Selling, General and Administrative Expense	5,746

Output Variable	Value in 1000 USD
Assets	13,698
Liabilities	4,828
Expenses	12,887
Revenues	356
Stockholders Equity	8,870
Net Income	-12,036
Comprehensive Net Income	-12,450
Economic Capital Ratio	30%

